NICE Clears Enhertu in HER2-Low Breast Cancer After England Raised Its Cost-Effectiveness Threshold

STRATEGIC NEWS WATCH — September 17, 2026

Today’s top developments:

NICE cleared Enhertu for NHS use in England in HER2-low unresectable or metastatic breast cancer — the first licensed targeted option for roughly 1,000 such women — two years after rejecting it, after the government revised NICE’s cost-effectiveness thresholds and methodology following the UK-US pharmaceutical pricing agreement (STAT)
Novo Nordisk signed a multi-target cardiometabolic drug-discovery partnership with Denmark’s Orbis Medicines worth up to $1.4 billion in development and commercial milestones, plus tiered royalties and an equity investment, for access to Orbis’s nGen platform for orally bioavailable synthetic macrocycles; the upfront payment was not disclosed (BioSpace)
Roche paid Dualitas Therapeutics $36.5 million up front — under 4% of a deal worth up to $1 billion in R&D and commercial milestones plus tiered royalties — to screen more than 300,000 novel bispecific antibody pairings in immunology and inflammation on its DualScreen platform (Fierce Biotech)
The FDA issued a warning letter dated September 4 to Bausch & Lomb over its Tampa, Florida sterile eye-drop plant, citing microbial contamination above acceptable limits across 2023–2025 — including Serratia marcescens and Stenotrophomonas maltophilia — and aseptic-technique lapses; no recall has been reported (Fierce Pharma)
CVS Health’s Aetna consolidated roughly four separate oncology prior authorizations per patient into a single bundled approval spanning medical oncology, radiation oncology and imaging, now live across eligible Medicaid states as of September 1, with Medicare and commercial planned for the first half of 2027 (Reuters)

What to Watch

Which appraisals reopen at the new NICE threshold — Enhertu failed in 2024 and passed in 2026 because the bar moved, not because the evidence did. The list of previously rejected medicines resubmitted against the revised methodology — not this single decision — is the real measure of what the UK-US pricing agreement bought.
Novo-Orbis committed capital — The $1.4 billion is milestones; the upfront and the equity investment remain undisclosed. The committed figure should surface in Novo’s or Orbis’s subsequent filings, and the named cardiometabolic targets are the tell — multi-target deals disclose those late or not at all.
Bausch & Lomb’s response and any recall — The warning letter is dated September 4 and the company must respond and meet the agency. A recall of sterile ophthalmic product is the escalation to look for, along with any tie between the Tampa site and a pending application — the point at which a warning letter does commercial damage.
Aetna’s commercial and Medicare expansion in H1 2027 — Bundling is live in Medicaid across eight states. The open question is whether the commercial book gets the same treatment on schedule, since that is where oncology utilization management is tightest and the administrative saving largest.
Whether the FDA’s hiring bottleneck shows up in dates — More than 3,000 staff lost, about 2,200 planned, roughly 1,600 still to fill as of June, with the rehiring function itself short-staffed. PDUFA date extensions and how Operation Trialblazer handles its October 30 application close will be the first concrete sign that review capacity is binding.

This brief highlights the edition’s top stories. Read the full September 17, 2026 edition → for all stories and analysis — or browse the Strategic News Watch archive.

Related Stories

Novartis Drops ALS for Lifonebart After Astrals Misses Every Endpoint — but Keeps the Molecule in Alzheimer’s

GSK Licenses a Preclinical Trispecific T Cell Engager From China’s Chimagen for Up to $750M in Myeloma

Scholar Rock’s Isemblyd Wins First Muscle-Targeted SMA Approval — at $310,000 With a Fracture Warning